Replimune Group Inc (NAS:REPL)
$ 7.9 0.79 (11.11%) Market Cap: 485.18 Mil Enterprise Value: 91.86 Mil PE Ratio: 0 PB Ratio: 1.17 GF Score: 30/100

Replimune Group Inc at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 07:15PM GMT
Release Date Price: $9.16 (+7.64%)
Anupam Rama JP Morgan Chase;Co.;Moderator

&-

Let's get started here and welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is [Anupam Rama], I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Priyanka Grover, [Lorea Hall, and Malcolm Kuno]. Our next presenting company is Replimune presenting on behalf of the company, we have Philip Astley-Sparke. Philip?

Philip Astley;Sparke Replimune Group
Inc. - CEO

Thank you, Anupam. Recognizing revenue and is an industry leader in oncolytic immunotherapy, we're progressing to asset RP1 and RP2 RP1. We plan to establish a broad skin cancer franchise in this regard, our foundational study is in PD-1 failed melanoma, where in 140 patient registrational cohort, we have shown benefit in approximately one in three patients by way of durable response and plan to file a BLA by the end of this year.

We've also generated data in multiple non-melanoma skin cancers, principally in cutaneous squamous cell carcinoma patients late

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot